Sinovac Biotech Ltd Financials
Sinovac Biotech Ltd (SVA) reported $386.0M in revenue for fiscal year 2025, up 6.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Sinovac’s current business mechanic is balance-sheet support, with legacy capital cushioning an operation that is now much smaller than the assets it controls.
In FY2024, reported profit and cash generation split apart: net income was$40.7M while operating cash flow was-$56.9M . Because the company also posted a large operating loss, that combination points to non-operating gains keeping earnings positive while the core business still used cash.
The balance sheet still carries stored earnings from earlier years: equity remained above
Short-term liquidity looks comfortable on paper, with a current ratio of 7.3x. But cash fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Sinovac Biotech Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Sinovac Biotech Ltd's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 13/100.
Sinovac Biotech Ltd's revenue grew 6.8% year-over-year to $386.0M, a solid pace of expansion. This earns a growth score of 12/100.
Sinovac Biotech Ltd carries a low D/E ratio of 0.11, meaning only $0.11 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 79/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.59, Sinovac Biotech Ltd holds $4.59 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 89/100.
Sinovac Biotech Ltd's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 7/100.
Sinovac Biotech Ltd posts a -4.5% return on equity (ROE), meaning it loses $4 for every $100 of shareholders' equity. This results in a returns score of 21/100. This is down from 0.5% the prior year.
Sinovac Biotech Ltd scores 1.19, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Sinovac Biotech Ltd passes 3 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Sinovac Biotech Ltd reported a net loss of $198.8M while operations used $512.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Sinovac Biotech Ltd reported an operating loss of $490.1M against $9.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Sinovac Biotech Ltd generated $386.0M in revenue in fiscal year 2025. This represents an increase of 6.8% from the prior year.
Sinovac Biotech Ltd's EBITDA was -$391.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.7% from the prior year.
Sinovac Biotech Ltd reported -$198.8M in net income in fiscal year 2025. This represents a decrease of 589.1% from the prior year.
Cash & Balance Sheet
Sinovac Biotech Ltd recorded an outflow of $561.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 267.1% from the prior year.
Sinovac Biotech Ltd held $488.2M in cash against $494.9M in long-term debt as of fiscal year 2025.
Sinovac Biotech Ltd paid $55.00 per share in dividends in fiscal year 2025.
Margins & Returns
Sinovac Biotech Ltd's gross margin was 67.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 6.8 percentage points from the prior year.
Sinovac Biotech Ltd's net profit margin was -51.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 62.8 percentage points from the prior year.
Sinovac Biotech Ltd's ROE was -4.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 5.0 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Sinovac Biotech Ltd invested $216.2M in research and development in fiscal year 2025. This represents a decrease of 20.1% from the prior year.
Sinovac Biotech Ltd invested $48.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 49.0% from the prior year.
Not reported for fiscal year 2025.
SVA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $386.0M+6.8% | $361.4M-23.1% | $470.2M-68.1% | $1.5B-92.4% | $19.4B+3692.5% | $510.6M+107.5% | $246.1M+7.1% | $229.7M+31.7% | $174.3M+140.7% | $72.4M+7.4% | $67.4M+7.1% | $62.9M-12.3% | $71.8M+45.8% | $49.2M-13.4% | $56.8M |
| Cost of Revenue | $124.0M-11.8% | $140.7M-4.2% | $146.9M-77.7% | $658.2M-33.4% | $988.9M+1372.0% | $67.2M+106.9% | $32.5M+31.3% | $24.7M+22.1% | $20.2M-9.6% | $22.4M+21.6% | $18.4M+18.9% | $15.5M-24.5% | $20.5M+7.4% | $19.1M-9.6% | $21.1M |
| Gross Profit | $262.0M+18.7% | $220.7M-31.7% | $323.3M-60.3% | $815.2M-95.6% | $18.4B+4044.0% | $443.4M+107.6% | $213.6M+4.2% | $204.9M+33.0% | $154.1M+208.0% | $50.0M+2.1% | $49.0M+3.3% | $47.5M-7.4% | $51.3M+70.2% | $30.1M-15.7% | $35.7M |
| R&D Expenses | $216.2M-20.1% | $270.7M-22.7% | $350.2M-26.8% | $478.7M+213.5% | $152.7M+213.2% | $48.8M+101.0% | $24.3M+10.7% | $21.9M+6.9% | $20.5M+62.0% | $12.6M+33.3% | $9.5M-13.2% | $10.9M+34.5% | $8.1M-52.3% | $17.0M+89.2% | $9.0M |
| SG&A Expenses | $333.0M-20.9% | $420.9M-29.6% | $598.3M-28.5% | $836.1M+38.9% | $602.1M+241.1% | $176.5M+45.3% | $121.5M-11.3% | $137.0M+56.8% | $87.4M+108.1% | $42.0M+12.0% | $37.5M+9.2% | $34.3M+2.2% | $33.6M+1.0% | $33.3M+39.8% | $23.8M |
| Operating Income | -$490.1M+3.0% | -$505.5M+29.2% | -$714.0M-40.3% | -$509.0M-102.9% | $17.6B+8070.1% | $215.6M+214.5% | $68.6M+51.3% | $45.3M-0.2% | $45.4M+8911.3% | $504K-86.4% | $3.7M+96.0% | $1.9M-81.0% | $9.9M+147.0% | -$21.2M-726.9% | $3.4M |
| Interest Expense | $9.8M+74.2% | $5.6M+14.1% | $4.9M+290.9% | $1.3M-55.4% | $2.8M+95.2% | $1.5M+123.5% | $650K-39.3% | $1.1M-31.8% | $1.6M-9.3% | $1.7M-9.9% | $1.9M-43.6% | $3.4M+12.4% | $3.0M+291.1% | $775K+101.8% | $384K |
| Income Tax | -$63.3M-3000.8% | $2.2M-94.0% | $36.4M+216.7% | $11.5M-99.7% | $3.4B+10867.4% | $31.4M+460.9% | $5.6M-46.5% | $10.5M+25.6% | $8.3M+213.0% | $2.7M-10.8% | $3.0M+44.3% | $2.1M+193.0% | -$2.2M-151.7% | -$884K-117.4% | $5.1M |
| Net Income | -$198.8M-589.1% | $40.7M+401.4% | -$13.5M-193.3% | $14.5M-99.8% | $8.1B+7259.1% | $110.4M+145.7% | $44.9M+106.3% | $21.8M-15.6% | $25.8M+4430.0% | -$596K+57.9% | -$1.4M+6.5% | -$1.5M-120.4% | $7.4M+139.7% | -$18.7M-2119.6% | -$845K |
| EPS (Diluted) | -$0.83 | $1.27 | -$0.19-195.0% | $0.20-99.8% | $113.44 | $0.97+136.6% | $0.41 | $0.34-24.4% | $0.45+4600.0% | -$0.01+66.7% | -$0.030.0% | -$0.03-123.1% | $0.13+148.1% | -$0.27 | -$0.02 |
SVA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.5B-30.8% | $12.3B-9.4% | $13.6B-3.0% | $14.0B-16.3% | $16.8B+781.4% | $1.9B+320.4% | $452.3M+22.3% | $369.8M+23.6% | $299.2M+41.6% | $211.4M+4.2% | $202.9M-14.9% | $238.5M-0.9% | $240.7M+15.3% | $208.8M-3.3% | $215.9M |
| Current Assets | $7.1B-33.6% | $10.6B-8.2% | $11.6B+2.6% | $11.3B-24.3% | $14.9B+857.4% | $1.6B+346.3% | $349.6M+23.0% | $284.2M+39.4% | $203.9M+55.9% | $130.7M+1.8% | $128.5M-17.0% | $154.8M-1.6% | $157.3M+24.5% | $126.3M-4.4% | $132.0M |
| Cash & Equivalents | $488.2M+45.6% | $335.3M-70.2% | $1.1B-71.0% | $3.9B-66.6% | $11.6B+1015.2% | $1.0B+581.7% | $152.7M-3.4% | $158.2M+38.2% | $114.4M+83.3% | $62.4M-2.2% | $63.8M-28.9% | $89.8M-15.7% | $106.5M+16.8% | $91.2M-12.5% | $104.3M |
| Inventory | $94.3M-2.7% | $96.9M-28.5% | $135.6M-22.6% | $175.3M-55.2% | $391.1M+269.6% | $105.8M+280.0% | $27.8M+11.0% | $25.1M+27.9% | $19.6M+39.1% | $14.1M-24.4% | $18.7M-0.3% | $18.7M+30.6% | $14.3M+36.1% | $10.5M+29.8% | $8.1M |
| Accounts Receivable | $286.3M-4.8% | $300.9M-29.2% | $424.9M-12.7% | $486.6M-48.4% | $942.7M+271.9% | $253.5M+122.9% | $113.7M+52.7% | $74.5M+12.5% | $66.2M+32.9% | $49.8M+27.7% | $39.0M-4.2% | $40.7M+27.5% | $31.9M+36.2% | $23.4M+31.4% | $17.8M |
| Goodwill | $12.6M-54.2% | $27.5M | $0 | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.1B+100.7% | $2.0B-61.4% | $5.3B-4.4% | $5.5B-28.6% | $7.8B+893.8% | $781.2M+680.4% | $100.1M+28.6% | $77.9M-36.2% | $122.1M+49.4% | $81.7M+23.0% | $66.4M-31.4% | $96.8M-0.3% | $97.1M+22.3% | $79.3M+12.3% | $70.6M |
| Current Liabilities | $1.5B+6.1% | $1.5B+12.3% | $1.3B+2.9% | $1.3B-50.1% | $2.5B+270.6% | $679.6M+679.4% | $87.2M+49.8% | $58.2M-37.1% | $92.5M+39.7% | $66.3M+14.0% | $58.1M-27.2% | $79.8M+62.4% | $49.2M+63.0% | $30.2M-23.7% | $39.5M |
| Long-Term Debt | $494.9M+31.7% | $375.8M+48.0% | $253.9M+2050.7% | $11.8M-25.1% | $15.8M-55.1% | $35.1M+491.4% | $5.9M-17.7% | $7.2M-78.1% | $33.0M-19.0% | $40.7M | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $4.4B-46.3% | $8.3B-0.6% | $8.3B-2.1% | $8.5B-5.6% | $9.0B+1105.0% | $746.5M+153.9% | $294.0M+16.0% | $253.4M+67.7% | $151.2M+30.6% | $115.8M-4.8% | $121.7M-3.9% | $126.6M-1.6% | $128.7M+9.3% | $117.7M-9.4% | $129.9M |
| Retained Earnings | $2.8B-58.8% | $6.8B+0.7% | $6.8B-0.2% | $6.8B-0.1% | $6.8B+4623.8% | $144.2M+154.3% | $56.7M+138.2% | $23.8M+160.8% | $9.1M+176.6% | -$11.9M-19.4% | -$10.0M-56.3% | -$6.4M | N/A | N/A | $2.7M |
SVA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$512.2M-800.3% | -$56.9M-141.0% | $138.6M+117.4% | -$798.1M-105.2% | $15.3B+3096.7% | $479.3M+1126.7% | $39.1M+391.9% | $7.9M-86.7% | $59.8M+529.8% | -$13.9M-430.1% | $4.2M+141.6% | -$10.1M-281.6% | $5.6M+134.3% | -$16.3M-216.6% | $13.9M |
| Capital Expenditures | $48.9M-49.0% | $96.0M-38.6% | $156.2M-50.2% | $313.9M-47.2% | $594.2M+366.1% | $127.5M+1099.5% | $10.6M+89.3% | $5.6M-52.9% | $11.9M-5.8% | $12.7M+138.8% | $5.3M-51.4% | $10.9M+112.6% | $5.1M-68.2% | $16.2M+4.5% | $15.5M |
| Free Cash Flow | -$561.1M-267.1% | -$152.9M-772.4% | -$17.5M+98.4% | -$1.1B-107.6% | $14.7B+4086.1% | $351.8M+1136.8% | $28.4M+1120.9% | $2.3M-95.1% | $47.8M+280.2% | -$26.6M-2340.8% | -$1.1M+94.8% | -$21.0M-4849.4% | $443K+101.4% | -$32.4M-2030.8% | -$1.5M |
| Investing Cash Flow | $4.4B+861.6% | $456.4M+116.9% | -$2.7B+55.7% | -$6.1B-104.8% | -$3.0B-1353.2% | -$204.8M-382.3% | -$42.5M-68.1% | -$25.3M-112.3% | -$11.9M-1.0% | -$11.8M-160.8% | -$4.5M+59.0% | -$11.0M-112.6% | -$5.2M | N/A | N/A |
| Financing Cash Flow | -$3.4B-316.9% | -$824.0M-830.4% | -$88.6M+70.4% | -$299.5M+84.3% | -$1.9B-422.8% | $592.6M+34014.3% | $1.7M-97.3% | $64.2M+4882.4% | -$1.3M-104.8% | $27.8M+214.8% | -$24.2M-555.8% | $5.3M-63.2% | $14.4M | N/A | N/A |
| Dividends Paid | $3.5B+273.2% | $947.0M+188.6% | $328.1M+32.6% | $247.4M-86.8% | $1.9B | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | $802K-86.3% | $5.9M |
Not reported in any period shown, so not listed: Share Buybacks.
SVA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.9%+6.8pp | 61.1%-7.7pp | 68.8%+13.4pp | 55.3%-39.6pp | 94.9%+8.1pp | 86.8%0.0pp | 86.8%-2.4pp | 89.2%+0.8pp | 88.4%+19.3pp | 69.1%-3.6pp | 72.7%-2.7pp | 75.4%+4.0pp | 71.4%+10.2pp | 61.2%-1.6pp | 62.8% |
| Operating Margin | -127.0% | -139.9% | -151.9% | -34.5%-125.5pp | 91.0%+48.8pp | 42.2%+14.4pp | 27.9%+8.1pp | 19.7%-6.3pp | 26.1%+25.4pp | 0.7%-4.8pp | 5.5%+2.5pp | 3.0%-10.9pp | 13.9%+56.8pp | -43.0%-48.9pp | 5.9% |
| Net Margin | -51.5%-62.8pp | 11.3%+14.1pp | -2.9%-3.9pp | 1.0%-41.0pp | 41.9%+20.3pp | 21.6%+3.3pp | 18.3%+8.8pp | 9.5%-5.3pp | 14.8%+15.6pp | -0.8%+1.3pp | -2.1%+0.3pp | -2.4%-12.8pp | 10.4%+48.5pp | -38.1%-36.6pp | -1.5% |
| Return on Equity | -4.5%-5.0pp | 0.5%+0.7pp | -0.2%-0.3pp | 0.2%-90.1pp | 90.3%+75.5pp | 14.8%-0.5pp | 15.3%+6.7pp | 8.6%-8.5pp | 17.1%+17.6pp | -0.5%+0.6pp | -1.2%0.0pp | -1.2%-7.0pp | 5.8%+21.7pp | -15.9%-15.3pp | -0.7% |
| Return on Assets | -2.3%-2.7pp | 0.3%+0.4pp | -0.1%-0.2pp | 0.1%-48.4pp | 48.5%+42.7pp | 5.8%-4.1pp | 9.9%+4.0pp | 5.9%-2.7pp | 8.6%+8.9pp | -0.3%+0.4pp | -0.7%-0.1pp | -0.6%-3.7pp | 3.1%+12.1pp | -9.0%-8.6pp | -0.4% |
| Current Ratio | 4.59-2.7x | 7.33-1.6x | 8.970.0x | 9.00+3.1x | 5.93+3.6x | 2.30-1.7x | 4.01-0.9x | 4.88+2.7x | 2.20+0.2x | 1.97-0.2x | 2.21+0.3x | 1.94-1.3x | 3.20-1.0x | 4.19+0.8x | 3.34 |
| Debt-to-Equity | 0.11+0.1x | 0.050.0x | 0.030.0x | 0.000.0x | 0.000.0x | 0.050.0x | 0.020.0x | 0.03-0.2x | 0.22-0.1x | 0.35-0.2x | 0.55-0.2x | 0.760.0x | 0.75+0.1x | 0.67+0.1x | 0.54 |
| FCF Margin | -145.4% | -42.3%-38.6pp | -3.7%+71.7pp | -75.5%-151.5pp | 76.0%+7.2pp | 68.9%+57.3pp | 11.6%+10.5pp | 1.0%-26.4pp | 27.4%+64.1pp | -36.7%-35.0pp | -1.6%+31.8pp | -33.4%-34.0pp | 0.6%+66.5pp | -65.8%-63.2pp | -2.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, FCF Margin.
Where Sinovac Biotech Ltd Ranks
Frequently Asked Questions
What is Sinovac Biotech Ltd's annual revenue?
Sinovac Biotech Ltd (SVA) reported $386.0M in total revenue for fiscal year 2025. This represents a 6.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sinovac Biotech Ltd's revenue growing?
Sinovac Biotech Ltd (SVA) revenue grew by 6.8% year-over-year, from $361.4M to $386.0M in fiscal year 2025.
Is Sinovac Biotech Ltd profitable?
No, Sinovac Biotech Ltd (SVA) reported a net income of -$198.8M in fiscal year 2025, with a net profit margin of -51.5%.
What is Sinovac Biotech Ltd's EBITDA?
Sinovac Biotech Ltd (SVA) had EBITDA of -$391.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Sinovac Biotech Ltd have?
As of fiscal year 2025, Sinovac Biotech Ltd (SVA) had $488.2M in cash and equivalents against $494.9M in long-term debt.
What is Sinovac Biotech Ltd's gross margin?
Sinovac Biotech Ltd (SVA) had a gross margin of 67.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Sinovac Biotech Ltd's net profit margin?
Sinovac Biotech Ltd (SVA) had a net profit margin of -51.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Sinovac Biotech Ltd pay dividends?
Yes, Sinovac Biotech Ltd (SVA) paid $55.00 per share in dividends during fiscal year 2025.
What is Sinovac Biotech Ltd's return on equity (ROE)?
Sinovac Biotech Ltd (SVA) has a return on equity of -4.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sinovac Biotech Ltd's free cash flow?
Sinovac Biotech Ltd (SVA) recorded an outflow of $561.1M in free cash flow during fiscal year 2025. This represents a -267.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sinovac Biotech Ltd's operating cash flow?
Sinovac Biotech Ltd (SVA) recorded an outflow of $512.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Sinovac Biotech Ltd's total assets?
Sinovac Biotech Ltd (SVA) had $8.5B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Sinovac Biotech Ltd's capital expenditures?
Sinovac Biotech Ltd (SVA) invested $48.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Sinovac Biotech Ltd spend on research and development?
Sinovac Biotech Ltd (SVA) invested $216.2M in research and development during fiscal year 2025.
What is Sinovac Biotech Ltd's current ratio?
Sinovac Biotech Ltd (SVA) had a current ratio of 4.59 as of fiscal year 2025, which is generally considered healthy.
What is Sinovac Biotech Ltd's debt-to-equity ratio?
Sinovac Biotech Ltd (SVA) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sinovac Biotech Ltd's return on assets (ROA)?
Sinovac Biotech Ltd (SVA) had a return on assets of -2.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sinovac Biotech Ltd's cash runway?
Based on fiscal year 2025 data, Sinovac Biotech Ltd (SVA) had $488.2M in cash against an annual operating cash burn of $512.2M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Sinovac Biotech Ltd's Altman Z-Score?
Sinovac Biotech Ltd (SVA) has an Altman Z-Score of 1.19, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Sinovac Biotech Ltd's Piotroski F-Score?
Sinovac Biotech Ltd (SVA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sinovac Biotech Ltd's earnings high quality?
Sinovac Biotech Ltd (SVA) reported a net loss of $198.8M while operations used $512.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Sinovac Biotech Ltd cover its interest payments?
Sinovac Biotech Ltd (SVA) reported an operating loss of $490.1M against $9.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Sinovac Biotech Ltd?
Sinovac Biotech Ltd (SVA) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.